Evidence map›Paper›PMID 27448942›Full record

Trial reportThe American journal of cardiology2016

Effects of Potassium Magnesium Citrate Supplementation on 24-Hour Ambulatory Blood Pressure and Oxidative Stress Marker in Prehypertensive and Hypertensive Subjects.

Wanpen Vongpatanasin, Poghni Peri-Okonny, Alejandro Velasco, Debbie Arbique, Zhongyun Wang, Priya Ravikumar, Beverly Adams-Huet, Orson W Moe, Charles Y C Pak

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01682837 (Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension), which is not on this map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01682837 phase2completednot on this map

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2012 to 2015Enrolled35ConditionsHypertensionArmsPotassium chloride powder, Potassium citrate powder, Potassium magnesium citrate powder, Placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. How Does Dietary Potassium Influence BP?Journal of the American Society of Nephrology : JASN · 2026
    Review
  7. Article
  8. Role of dietary potassium and salt substitution in the prevention and management of hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Wanpen VongpatanasinCardiology Division Hypertension Section, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: wanpen.vongpatanasin@utsouthwestern.edu.
Poghni Peri-OkonnyCardiology Division Hypertension Section, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Alejandro VelascoCardiology Division Hypertension Section, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Debbie ArbiqueCardiology Division Hypertension Section, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Zhongyun WangCardiology Division Hypertension Section, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Priya RavikumarCharles and Jane Pak Center of Mineral Metabolism and Clinical Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Beverly Adams-HuetDivision of Biostatistics, Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.
Orson W MoeCharles and Jane Pak Center of Mineral Metabolism and Clinical Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Nephrology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas.
Charles Y C PakCharles and Jane Pak Center of Mineral Metabolism and Clinical Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
The University of Texas Southwestern Medical Center · US

Funding

UT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9M
NIDDK NIH HHS P30 DK079328
6 · The paper itself

Abstract

Diet rich in fruits, vegetables, and dairy products, known as the Dietary Approaches to Stop Hypertension (DASH) diet, is known to reduce blood pressure (BP) in hypertensive patients. More recently, the DASH diet was shown to reduce oxidative stress in hypertensive and nonhypertensive humans. However, the main nutritional components responsible for these beneficial effects of the DASH diet remain unknown. Because the DASH diet is rich in potassium (K), magnesium (Mg), and alkali, we performed a randomized, double-blinded, placebo-controlled study to compare effects of potassium magnesium citrate (KMgCit), potassium chloride (KCl), and potassium citrate (KCit) to allow dissociation of the three components of K, Mg, and citrate on 24-hour ambulatory BP and urinary 8-isoprostane in hypertensive and prehypertensive subjects, using a randomized crossover design. We found that KCl supplementation for 4 weeks induced a significant reduction in nighttime SBP compared with placebo (116 ± 12 vs 121 ± 15 mm Hg, respectively, p <0.01 vs placebo), whereas KMgCit and KCit had no significant effect in the same subjects (118 ± 11 and 119 ± 13 mm Hg, respectively, p >0.1 vs placebo). In contrast, urinary 8-isoprostane was significantly reduced with KMgCit powder compared with placebo (13.5 ± 5.7 vs 21.1 ± 10.5 ng/mgCr, respectively, p <0.001), whereas KCl and KCit had no effect (21.4 ± 9.1 and 18.3 ± 8.4, respectively, p >0.1 vs placebo). In conclusion, our study demonstrated differential effects of KCl and KMgCit supplementation on BP and the oxidative stress marker in prehypertensive and hypertensive subjects. Clinical significance of the antioxidative effect of KMgCit remains to be determined in future studies.

Indexed as

Oxidative StressAdultAgedAntihypertensive AgentsBlood PressureBlood Pressure Monitoring, AmbulatoryCitratesCross-Over StudiesDietary SupplementsDinoprostDouble-Blind MethodDrug CombinationsFemaleHumansHypertensionLinear Models8-epi-prostaglandin F2alphaAntihypertensive AgentsCitratesDinoprostDrug CombinationsMagnesium CompoundsPotassiumPotassium ChloridePotassium CitratePotassium Compoundspotassium-magnesium citrate

Identifiers

PMID27448942
PMCPMC5021576
OpenAlexW2469479297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.